Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Michael Cerniglia"'
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 37-42 (2022)
Introduction: Although guidelines exist for appropriate use of chemotherapy in the metastatic setting based on performance status, such recommendations are less readily available for immune checkpoint inhibitors (ICIs). We sought to determine whether
Externí odkaz:
https://doaj.org/article/f5e6d76ebb59474982a88e03a2ec25e8
Publikováno v:
BMJ case reports. 15(8)
For hepatocellular carcinoma, the IMbrave150 trial demonstrated that combination atezolizumab and bevacizumab had significantly better overall survival compared with sorafenib in patients with unresectable disease. However, as more immune checkpoint
Autor:
Sunnie S. Kim, Jia Zeng, Richard M. Goldberg, Philip A. Philip, Mohamed Salem, W. Michael Korn, Heinz-Josef Lenz, Anthony F. Shields, Ari M. VanderWalde, John L. Marshall, Jimmy J. Hwang, Yasmine Baca, Michael J. Pishvaian, Axel Grothey, Joanne Xiu, Michael Cerniglia
Supplemental Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20cad4ec26e1e4a56d1246bbd8e74fc2
https://doi.org/10.1158/1535-7163.22522530.v1
https://doi.org/10.1158/1535-7163.22522530.v1
Autor:
Sunnie S. Kim, Jia Zeng, Richard M. Goldberg, Philip A. Philip, Mohamed Salem, W. Michael Korn, Heinz-Josef Lenz, Anthony F. Shields, Ari M. VanderWalde, John L. Marshall, Jimmy J. Hwang, Yasmine Baca, Michael J. Pishvaian, Axel Grothey, Joanne Xiu, Michael Cerniglia
Supplementary Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42a7db21a3661a5bec2ef734ab04f4bb
https://doi.org/10.1158/1535-7163.22522527.v1
https://doi.org/10.1158/1535-7163.22522527.v1
Autor:
Antoni Ribas, Begonya Comin-Anduix, Thomas G. Graeber, Thinle Chodon, Bjoern Titz, Michael Cerniglia, David Foulad, Lidia Robert, Deborah J.L. Wong, Amanda Lassen, Earl Avramis, Mohammad Atefi
Purpose: PD-L1 is the main ligand for the immune inhibitory receptor PD-1. This ligand is frequently expressed by melanoma cells. In this study, we investigated whether PD-L1 expression is controlled by melanoma driver mutations and modified by oncog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dfbc2f2b0a21e3861c54fc6c8ba22cc
https://doi.org/10.1158/1078-0432.c.6521649
https://doi.org/10.1158/1078-0432.c.6521649
Autor:
Antoni Ribas, Begonya Comin-Anduix, Thomas G. Graeber, Thinle Chodon, Bjoern Titz, Michael Cerniglia, David Foulad, Lidia Robert, Deborah J.L. Wong, Amanda Lassen, Earl Avramis, Mohammad Atefi
PDF file - 247KB, MAPK pathway is almost inactive in resting PBMCs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f944be37873d04b3ffda49b9be5fec
https://doi.org/10.1158/1078-0432.22449408
https://doi.org/10.1158/1078-0432.22449408
Autor:
Antoni Ribas, Begonya Comin-Anduix, Thomas G. Graeber, Thinle Chodon, Bjoern Titz, Michael Cerniglia, David Foulad, Lidia Robert, Deborah J.L. Wong, Amanda Lassen, Earl Avramis, Mohammad Atefi
PDF file - 206KB, Restoration of the MAPK pathway activity by vemurafenib in lymphocytes exposed to PD-L1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ee34b959f0846a2e3dc51913542e108
https://doi.org/10.1158/1078-0432.22449405.v1
https://doi.org/10.1158/1078-0432.22449405.v1
Autor:
Joanne Xiu, Michael J. Pishvaian, Ari M. Vanderwalde, Jia Zeng, Yasmine Baca, Sunnie S. Kim, John L. Marshall, W. Michael Korn, Anthony F. Shields, Axel Grothey, Heinz-Josef Lenz, Philip A. Philip, Mohamed E. Salem, Jimmy J. Hwang, Richard M. Goldberg, Michael Cerniglia
Publikováno v:
Mol Cancer Ther
The prevalence of homologous recombination–DNA damage response (HR-DDR) genetic alterations is of therapeutic interest in gastroesophageal cancers. This study is a comprehensive assessment of HR-DDR mutation prevalence across gastroesophageal adeno
Autor:
Roger S. Lo, Amanda Lassen, David Foulad, Earl Avramis, Antoni Ribas, Jennifer Tsoi, Begonya Comin-Anduix, Lidia Robert, Deborah J.L. Wong, Thomas G. Graeber, Michael Cerniglia, Geetha Avarappatt, Mohammad Atefi, Ahmed A. Samatar
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Molecular Cancer
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname
Molecular Cancer
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
In melanoma, dysregulation of the MAPK pathway, usually via BRAF(V600) or NRAS(Q61) somatic mutations, leads to constitutive ERK signaling. While BRAF inhibitors are initially effective for BRAF-mutant melanoma, no FDA-approved targeted therapies exi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef00a5b60c188a2e969ec41344e23397
http://hdl.handle.net/2072/426900
http://hdl.handle.net/2072/426900
Autor:
Inbal Abraham-Davidi, Zoran Galić, Antoni Ribas, Orit Rosenblatt-Rosen, Michael Cerniglia, Gardenia Cheung-Lau, Daniel Sanghoon Shin, Helena Escuin-Ordinas, Begoña Comin-Anduix, Maria Alexandrovna Aleshin, Caroline Porter
Publikováno v:
Cancer Research. 81:1551-1551
Introduction: A small subset of T cells from patients treated with MART-1 engineered adoptive T cell transfer (ACT) were found to co-express Yamanaka transcription factors SOX2, OCT3/4, and NANOG (TSON). Identifying these T cells may have potential u